Symbol | Exchange | Currency |
|---|
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Technology and Financials sectors led shares higher. At the close in NYSE,...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the FDA has granted Breakthrough Therapy designation to its leukemia drug Tibsovo (ivosidenib) for the treatment of...
Geron Corporation’s (NASDAQ:GERN) shares have surged 40% so far this year compared with the industry’s growth of 5.2%, riding on the progress of its sole pipeline...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 320.02 | 320.24 | 313.28 | +5.00 | +1.59% | 19.00M | NASDAQ | |||
| 2,337.35 | 2,337.35 | 2,293.04 | +22.58 | +0.98% | 1.26M | NASDAQ | |||
| 226.42 | 228.44 | 222.88 | -0.36 | -0.16% | 12.24M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 46.65 | 49.81 | 45.72 | -4.53 | -8.85% | 79.21M | NYSE | |||
| 7.59 | 7.71 | 7.34 | +0.29 | +3.97% | 16.21M | NYSE | |||
| 1.15 | 1.22 | 1.11 | -0.0500 | -4.17% | 21.92M | NYSE | |||
| 0.8223 | 0.00 | 0.00 | +0.0228 | +2.85% | 3.71M | NYSE | |||
| 117.00 | 117.64 | 114.46 | +1.62 | +1.40% | 8.57M | NYSE | |||
| 15.93 | 16.29 | 15.02 | +0.99 | +6.63% | 8.64M | NYSE | |||
| 36.08 | 36.18 | 35.89 | +0.57 | +1.61% | 67.35K | OTC Markets | |||
| 67.53 | 68.50 | 65.01 | +4.46 | +7.07% | 12.59M | NYSE | |||
| 3.39 | 3.57 | 3.12 | +0.230 | +7.28% | 424.48K | NASDAQ | |||
| 20.09 | 21.02 | 19.41 | -1.06 | -5.01% | 92.09M | NYSE | |||
| 0.00007 | 0.00 | 0.00 | 0.00000 | 0.00% | 0.00 | OTC Markets |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.